Zeon Lifesciences Targets U.S. Nutraceutical Market with FDA Approval

With the successful registration of its production facility under U.S. Food and Drug Administration oversight, India-based Zeon Lifesciences has cleared a critical regulatory hurdle. The move signals a strategic push by the manufacturer to supply dietary supplements to American brands while meeting rigorous federal safety and quality standards.

Today, 16:54· Corp and Tech· 617 reads

Zeon Lifesciences Targets U.S. Nutraceutical Market with FDA Approval

The company’s facility has passed clearance inspections mandated by the Food Safety Modernization Act, a key prerequisite for food and supplement exporters. Beyond basic registration, Zeon secured NSF certification, confirming compliance with 21 CFR Part 111—the FDA’s current Good Manufacturing Practice regulations. This dual-layer validation aims to attract international partners seeking a reliable CDMO provider in India that can navigate the complexities of the American regulatory landscape.

Suresh Garg, Founder and Managing Director, emphasized that the firm is realigning its core infrastructure to match global expectations. The company is currently scaling its compliance operations, including U.S.-specific packaging standards, finished-product testing, and rigorous documentation processes. By integrating these systems, Zeon intends to position itself as a long-term manufacturing partner for brands that prioritize supply chain transparency and regulatory consistency in the competitive nutraceutical sector.

Zeon Lifesciences Targets U.S. Nutraceutical Market with FDA Approval

Comments (0)